| Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun and Michael Tobias Stumpp on November 23, 2004 and is headquartered in Zurich, Switzerland. |
|
